Pediatr. praxi. 2021;22(1):12-15 [Prakt. lékáren. 2021; 17(1): 22-24]

Current therapeutic options of erdosteine

Marek Lapka
Ústav farmakologie 3. LF UK, Praha

Erdosteine belongs to the commonly used mucolytic. The mechanism of action of this substance lies in regulating the mucus viscosity, its formation and also mucociliary transport. However, the peculiarity of erdosteine consists in its antioxidant, anti-inflammatory and antibacterial effect. The article discusses these characteristics in the context of current information with a focus also on the paediatric population.

Keywords: mucolytics, cough, erdosteine, lower respiratory tract infection.

Published: March 25, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lapka M. Current therapeutic options of erdosteine. Pediatr. praxi. 2021;22(1):12-15.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Miyake K, Kaise T, et al. The effect of erdosteine and its active metabolite on reactive oxygen species production by inflammatory cells. Inflamm Res. 1999;48(4):205-9 Go to original source... Go to PubMed...
    2. Marabini L, Calò R, Braga PC. Protective effect of erdosteine metabolite I against hydrogen peroxide‑induced oxidative DNA‑damage in lung epithelial cells. Arzneimittelforschung. 2011;61(12):700-6. Go to original source...
    3. Erdem A, Gedikli E, Yersal N, et al. Protective role of erdosteine pretreatment on oleic acid‑induced acute lung injury. J Surg Res. 2017; 213: 234-242. Go to original source... Go to PubMed...
    4. Park JS, Park MY, Cho YJ, et al. Anti‑inflammatory effect of erdosteine in lipopolysaccharide‑stimulated RAW 264.7 cells. Inflammation. 2016;39(4):1573-81. Go to original source... Go to PubMed...
    5. Braga PC, Dal Sasso M, Culici M, Verducci P, et al. Effect of metabolite I of erdosteine on the release of human neutrophil elastase. Pharmacology. 2006;77(3):150-4. Go to original source... Go to PubMed...
    6. Braga PC, et al. Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. Chemotherapy. 2001; 47(3): 208-214. Go to original source... Go to PubMed...
    7. Dal Sasso M, Bovio C, Culici M, Braga PC. The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone. Drugs Exp Clin Res. 2002; 28(2-3): 75-82
    8. Bolser DC. Cough suppressant and pharmacologic protussive therapy: ACCP evidence‑based clinical practice guidelines. Chest. 2006; 129(1 Suppl): 238S-49S. Go to original source... Go to PubMed...
    9. Moretti M, et al. The effect of long‑term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res. 2004; 30(4): 143-152.
    10. Dal Negro RW, Visconti M, et al. Changes in blood ROS, e‑NO, and some pro‑inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm Pharmacol Ther. 2008; 21(2): 304-308. Go to original source... Go to PubMed...
    11. Dal Negro RW, Wedzicha JA, Iversen M, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017; 50(4): 1700711. Go to original source... Go to PubMed...
    12. Cazzola M, Floriani I, Page CP. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta‑analysis of individual patient data. Pulm Pharmacol Ther. 2010; 23(2): 135-144. Go to original source... Go to PubMed...
    13. Musil J, Fila L, Kolek V. Doporučený postup ČPFS pro diagnostiku a léčbu exacerbace CHOPN. Sekce pro nemoci s bronchiální obstrukcí ČPFS, 2019. Dostupné na: www.pneumologie.cz/upload/1583105754.4482.pdf
    14. Rogliani P, Matera MG, Page C, Puxeddu E, et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N‑acetylcysteine. Respir Res. 2019;20(1):104. Go to original source... Go to PubMed...
    15. Titti G, Lizzio A et al. A controlled multicenter paediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine. Int. J. Clin. Pharmacol. Ther., 38, 402, 2000. Go to original source... Go to PubMed...
    16. Balli F, Bergamini B, et al. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children. Int J Clin Pharmacol Ther. 2007; 45(1): 16-22. Go to original source... Go to PubMed...
    17. Kopřiva F. Sledování ATB léčby dětských pacientů s recidivujícími respiračními infekcemi v letech 2013-2016 a erdosteinu aneb co nám řekla "ERICA". Vox pediatriae. 2017; 17 (1): 42-44.
    18. Yenny, Naning R, Setyati A. Randomized controlled trial of erdosteine for acute cough in children with colds. Paediatr Indones. 2011; 51(2): 111-115. Go to original source...
    19. Santus P, Tursi F, et al. 2020. Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients discharged at home. Multidisciplinary Respiratory Medicine, 15. Go to original source... Go to PubMed...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.